187 related articles for article (PubMed ID: 27301657)
1. Mortality trends in U.S. adults with septic shock, 2005-2011: a serial cross-sectional analysis of nationally-representative data.
Goto T; Yoshida K; Tsugawa Y; Filbin MR; Camargo CA; Hasegawa K
BMC Infect Dis; 2016 Jun; 16():294. PubMed ID: 27301657
[TBL] [Abstract][Full Text] [Related]
2. Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.
Vail E; Gershengorn HB; Hua M; Walkey AJ; Rubenfeld G; Wunsch H
JAMA; 2017 Apr; 317(14):1433-1442. PubMed ID: 28322415
[TBL] [Abstract][Full Text] [Related]
3. Continuation of Statin Therapy and Vasopressor Use in Septic Shock.
Zechmeister C; Hurren J; McNorton K
Ann Pharmacother; 2015 Jul; 49(7):790-5. PubMed ID: 25896127
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock.
Roberts RJ; Miano TA; Hammond DA; Patel GP; Chen JT; Phillips KM; Lopez N; Kashani K; Qadir N; Cairns CB; Mathews K; Park P; Khan A; Gilmore JF; Brown ART; Tsuei B; Handzel M; Chang AL; Duggal A; Lanspa M; Herbert JT; Martinez A; Tonna J; Ammar MA; Nazer LH; Heavner M; Pender E; Chambers L; Kenes MT; Kaufman D; Downey A; Brown B; Chaykosky D; Wolff A; Smith M; Nault K; Gong MN; Sevransky JE; Lat I;
Crit Care Med; 2020 Oct; 48(10):1445-1453. PubMed ID: 32706559
[TBL] [Abstract][Full Text] [Related]
5. Intensity of Vasopressor Therapy for Septic Shock and the Risk of In-Hospital Death.
Brand DA; Patrick PA; Berger JT; Ibrahim M; Matela A; Upadhyay S; Spiegler P
J Pain Symptom Manage; 2017 May; 53(5):938-943. PubMed ID: 28062334
[TBL] [Abstract][Full Text] [Related]
6. Timing of vasopressor initiation and mortality in septic shock: a cohort study.
Beck V; Chateau D; Bryson GL; Pisipati A; Zanotti S; Parrillo JE; Kumar A;
Crit Care; 2014 May; 18(3):R97. PubMed ID: 24887489
[TBL] [Abstract][Full Text] [Related]
7. Practice Patterns and Outcomes Associated With Choice of Initial Vasopressor Therapy for Septic Shock.
Fawzy A; Evans SR; Walkey AJ
Crit Care Med; 2015 Oct; 43(10):2141-6. PubMed ID: 26079345
[TBL] [Abstract][Full Text] [Related]
8. A time-sensitive analysis of the prognostic utility of vasopressor dose in septic shock.
Chotalia M; Matthews T; Arunkumar S; Bangash MN; Parekh D; Patel JM
Anaesthesia; 2021 Oct; 76(10):1358-1366. PubMed ID: 33687732
[TBL] [Abstract][Full Text] [Related]
9. Severe sepsis and septic shock in patients with pre-existing non-cardiac pulmonary hypertension: contemporary management and outcomes.
Tsapenko MV; Herasevich V; Mour GK; Tsapenko AV; Comfere TB; Mankad SV; Cartin-Ceba R; Gajic O; Albright RC
Crit Care Resusc; 2013 Jun; 15(2):103-9. PubMed ID: 23931041
[TBL] [Abstract][Full Text] [Related]
10. Effects of thiamine on vasopressor requirements in patients with septic shock: a prospective randomized controlled trial.
Petsakul S; Morakul S; Tangsujaritvijit V; Kunawut P; Singhatas P; Sanguanwit P
BMC Anesthesiol; 2020 Nov; 20(1):280. PubMed ID: 33167911
[TBL] [Abstract][Full Text] [Related]
11. Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data.
Kadri SS; Rhee C; Strich JR; Morales MK; Hohmann S; Menchaca J; Suffredini AF; Danner RL; Klompas M
Chest; 2017 Feb; 151(2):278-285. PubMed ID: 27452768
[TBL] [Abstract][Full Text] [Related]
12. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study).
Póvoa PR; Carneiro AH; Ribeiro OS; Pereira AC;
Crit Care Med; 2009 Feb; 37(2):410-6. PubMed ID: 19114885
[TBL] [Abstract][Full Text] [Related]
13. Positive predictive value of International Classification of Diseases, 10th revision, diagnosis codes for cardiogenic, hypovolemic, and septic shock in the Danish National Patient Registry.
Lauridsen MD; Gammelager H; Schmidt M; Nielsen H; Christiansen CF
BMC Med Res Methodol; 2015 Mar; 15():23. PubMed ID: 25888061
[TBL] [Abstract][Full Text] [Related]
14. Impact of Hyperoncotic Albumin on Duration of Vasopressor Support in Septic Shock: A Propensity Score-Matched Analysis.
Flannery AH; Owen GD; Coz A; Thompson Bastin ML; Patel K
Ann Pharmacother; 2021 May; 55(5):584-591. PubMed ID: 33016080
[TBL] [Abstract][Full Text] [Related]
15. Identifying Vasopressor and Inotrope Use for Health Services Research.
Fawzy A; Bradford M; Lindenauer PK; Walkey AJ
Ann Am Thorac Soc; 2016 Mar; 13(3):414-8. PubMed ID: 26653145
[TBL] [Abstract][Full Text] [Related]
16. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.
Vasu TS; Cavallazzi R; Hirani A; Kaplan G; Leiby B; Marik PE
J Intensive Care Med; 2012; 27(3):172-8. PubMed ID: 21436167
[TBL] [Abstract][Full Text] [Related]
17. CT-proAVP IS NOT A GOOD PREDICTOR OF VASOPRESSOR NEED IN SEPTIC SHOCK.
Laribi S; Lienart D; Castanares-Zapatero D; Collienne C; Wittebole X; Laterre PF
Shock; 2015 Oct; 44(4):330-5. PubMed ID: 26196839
[TBL] [Abstract][Full Text] [Related]
18. Hyperlactatemia is an independent predictor of mortality and denotes distinct subtypes of severe sepsis and septic shock.
Thomas-Rueddel DO; Poidinger B; Weiss M; Bach F; Dey K; Häberle H; Kaisers U; Rüddel H; Schädler D; Scheer C; Schreiber T; Schürholz T; Simon P; Sommerer A; Schwarzkopf D; Weyland A; Wöbker G; Reinhart K; Bloos F;
J Crit Care; 2015 Apr; 30(2):439.e1-6. PubMed ID: 25466313
[TBL] [Abstract][Full Text] [Related]
19. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials.
Oba Y; Lone NA
J Crit Care; 2014 Oct; 29(5):706-10. PubMed ID: 24857641
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock.
Patel GP; Grahe JS; Sperry M; Singla S; Elpern E; Lateef O; Balk RA
Shock; 2010 Apr; 33(4):375-80. PubMed ID: 19851126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
